Paclitaxel and docetaxel are active in the treatment of patients with advanced ovarian cancer. The taxanes in various dose schedules achieve response rates of 10-50% with a median overall survival of 10-12 months in patients with platinum-refractory disease. Paclitaxel has activity in chemotherapy-naive patients when administered alone or in combination with platinum. The role of intraperitoneal paclitaxel remains to be defined.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
ovarian cancer
8
taxanes ovarian
4
cancer treatment
4
treatment paclitaxel
4
paclitaxel docetaxel
4
docetaxel active
4
active treatment
4
treatment patients
4
patients advanced
4
advanced ovarian
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!